The future of asthma research and development: a roadmap from the European Asthma Research and Innovation Partnership (EARIP)
File(s)The future of asthma research and development.docx (259.08 KB)
Accepted version
Author(s)
Type
Journal Article
Abstract
Asthma is highly prevalent and associated with high morbidity and mortality. It affects 30–50 million people in Europe, often starting in infancy and persisting throughout life. Asthma is a major global health challenge, affecting more than 300 million people worldwide and at least 10% of all Europeans [1]. People with asthma live at risk of life-threatening asthma attacks, leading to over 500 000 hospitalisations each year. Approximately 5–10% of asthma cases are so severe that current treatments do not work. The Framework Programme 7-funded European Asthma Research and Innovation Partnership (EARIP; www.EARIP.eu) was established in 2013 to harmonise efforts to reduce mortality and morbidity from asthma by agreeing the most important research priorities across relevant stakeholders in Europe. This is essential to address the significant impact of asthma on the individual, healthcare systems and national and European economies, outlined in the accompanying editorial in this issue of the European Respiratory Journal [2]. EARIP produced an evidence- and consensus-based list of the research priorities (a “roadmap”) and investment needed to reduce asthma deaths and hospitalisations. By identifying the priorities, a coordinated effort can be made to fast-track change to better manage, prevent and cure asthma [3]. The roadmap will be the foundation on which future EU, national and international research funding programmes can transform asthma outcomes throughout Europe. The roadmap is the product of a comprehensive multi-stage process, led by the European Lung Foundation and Asthma UK (figure 1) [4]. Multiple stakeholder groups informed the roadmap process to ensure scientific accuracy, clinical relevance and outcomes that reflect the priorities of patients and caregivers, with an overarching steering board. A final consensus workshop brought together 28 experts from 15 European countries comprising: patients, patient organisations, primary healthcare professionals (HCPs), secondary HCPs, researchers, industry representatives and policy influencers. A full list of the roadmap contributors is available at www.EARIP.eu/roadmap. The rest of this article describes its development and outcomes.
Date Issued
2017-05-01
Online Publication Date
2018-05-01T06:00:19Z
Date Acceptance
2016-12-05
ISSN
1399-3003
Publisher
European Respiratory Society: ERJ
Journal / Book Title
European Respiratory Journal
Volume
49
Issue
5
Copyright Statement
© ERS 2017. This is an author-submitted, peer-reviewed version of a manuscript that has been accepted for publication in the European Respiratory Journal, prior to copy-editing, formatting and typesetting. This version of the manuscript may not be duplicated or reproduced without prior permission from the copyright owner, the European Respiratory Society. The publisher is not responsible or liable for any errors or omissions in this version of the manuscript or in any version derived from it by any other parties. The final, copy-edited, published article, which is the version of record, is available without a subscription 18 months after the date of issue publication
Source Database
pubmed
Sponsor
Commission of the European Communities
Grant Number
115010
Subjects
Science & Technology
Life Sciences & Biomedicine
Respiratory System
DELPHI EXERCISE
MANAGEMENT
PRIORITIES
PREVENT
EAACI
TOOLS
CURE
EU
11 Medical And Health Sciences
Publication Status
Published
Article Number
ARTN 1602295